Business Wire·Aug 10, 2026, 7:30 AM ET

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics announced positive topline results from the Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent polycythemia vera patients.
The trial met its primary endpoint, with 88% of divesiran-treated patients achieving a clinical response compared to 19% in the placebo group (p<0.0001).
Both dose groups showed substantial efficacy, with response rates of 93.8% for the every-six-weeks (Q6W) regimen & 81.3% for the every-twelve-weeks (Q12W) regimen.
A key secondary endpoint was met, showing a significant reduction in mean phlebotomy rates (0.2 for divesiran vs. 2.1 for placebo).
Divesiran demonstrated improvements in hematocrit control, iron markers, & patient-reported symptom scores.
The drug was well tolerated with no new safety findings; injection site reactions were infrequent & self-limiting.
Silence Therapeutics plans to initiate a Phase 3 PV trial evaluating divesiran Q12W vs. placebo in the first half of 2027.
An investor conference call & webcast to discuss these results is scheduled for August 10, 2026, at 8:00 a.m. ET.
Divesiran holds FDA Fast Track & Orphan Drug designations for polycythemia vera.